
Prediction
- Microbiome data
- Digital twin simulation
- Metabolic output prediction
Enbiosis “The World’s First Digital Twin & AI Powered Nutraceutical Formulation Engine”
Science & Technology
Enbiosis began as an AI-powered, microbiome-based personalized food and supplement recommendations platform. Over time, this foundation evolved into a design engine that models and predicts these transformations to guide targeted formulation development.
Our Story
Enbiosis began as an AI-powered, microbiome-based personalized food and supplement recommendations platform. Over 15+ years of experience, our unique algorithm has been validated through four Q1 publications and partnerships across the UK, the US, Canada, Latin America, the Middle East and Southeast Asia.
Building on this foundation, we evolved beyond personalized recommendations into a formulation platform. Translating microbiome insights into targeted nutraceutical designs.
The result is Enbiosis 2.0: a formulation engine powered by Digital Twin & AI, supported by clinical evidence.
Step 1
Developing digital twin models of the human gut microbiome to simulate how microbial communities process different inputs and generate metabolic outputs.
Step 2
Identifying target metabolic pathways and key microbial functions associated with specific health outcomes through simulation and scientific validation.
Step 3
Using AI-driven retrosynthesis to identify food-grade precursors that can be converted by the microbiome into target metabolites.
Step 4
Translating these insights into ready-to-use nutraceutical formulations, designed for scalable integration across global markets.
The Technology
Through digital twin technology, we identify condition-specific metabolic targets and design research-backed, food-grade formulations to support outcomes across gastrointestinal, ocular, cognitive, mental health, and beyond.
Standard Approach
Generic ingredients, limited data, and unpredictable outcomes.
Enbiosis Approach
We simulate how the microbiome transforms ingredients into functional metabolites before a formulation ever reaches production.
The Pipeline




Validation
Our platform is being validated through pilot and randomized clinical studies across multiple health areas, starting with ophthalmology and expanding into metabolic, gastrointestinal, and urology-focused indications.
Dry Eye Disease (DED), Pilot study completed in DED
Type 2 Diabetes Mellitus, Weight Management
Ulcerative Colitis
Psoriasis
Hypogonadism
Alzheimer’s Disease, Parkinson’s Disease
Publications
Our research is published in peer-reviewed journals across gastroenterology, microbiome science and machine learning.
Tunali V, Arslan NÇ, Ermiş BH, et al. · 2024 · DOI 10.14309/ajg.0000000000002862

Tunali V, Arslan NÇ, Derviş Hakim G, et al. · 2026 · DOI 10.1080/19490976.2026.2719125

Karakan T, Gundogdu A, Alagözlü H, et al. · 2022 · DOI 10.1080/19490976.2022.2138672

Arslan NÇ, Gündoğdu A, Tunali V, et al. · 2022 · DOI 10.3390/jcm11226612

Gundogdu A, Karis G, Killpartrick A, et al. · 2024 · DOI 10.1002/mnfr.202300780

Nalbantoglu Ö, Ermiş B, Gündoğdu A · 2025 · DOI 10.1016/j.bspc.2025.108146